Dapagliflozin is cost effective compared to DPP4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands Gallery Dapagliflozin is cost effective compared to DPP4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands Clinical track Dapagliflozin is cost effective compared to DPP4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands Door N. van der Linden (Den Haag)|oktober 30th, 2020|Clinical track|0 Reacties Lees meer
